Trending...
- How AI Exposed Major Flaws in the Foundation & Structure of Technology, Hardware & the Internet & Phinge's® Patented Netverse®, App-less Solution
- Only 7 Days Left for Early Bird Registration to the OpenSSL Conference 2025
- Joint Venture for Expansion Into Asset-Backed Real Estate; $100 Million Initiative via Offering of Shares at Over $4 for Digital Assets: $OFAL
BOSTON, May 20, 2024 ~ Journalist: HotSpot Therapeutics, Inc. has announced that they will be presenting additional preclinical data from their MALT1 program at the 4th American Association for Cancer Research (AACR) International Meeting. The meeting, titled "Advances in Malignant Lymphoma," will take place from June 19-22, 2024 in Philadelphia, PA.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
The company, known for pioneering the discovery and development of oral, small molecule allosteric therapies targeting regulatory sites on proteins referred to as "natural hotspots," will be sharing their findings on the highly differentiated mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) program.
More on The PennZone
- DATA BREACH ALERT: Edelson Lechtzin LLP is Investigating data privacy Claims on Behalf of TransUnion Customers
- Integris Composites Joins Pacific Future Forum in Tokyo
- BusinessRate Selects New Jersey Therapy & Life Coaching as Best Couselors
- IRL Investigations Combines Decades of Experience with Modern Digital Expertise
- New Leadership Model – Never Fire Anyone – Released Today
The presentation, titled "Targeting the CBM Signalosome with a MALT1 Scaffolding Inhibitor for Treatment of Non-Hodgkin Lymphomas," will take place on Thursday, June 20, 2024 from 5:30-7:30 PM ET at the Sheraton Philadelphia Downtown. The publication number for this presentation is PO-036.
HotSpot Therapeutics' innovative approach to targeting regulatory sites on proteins has shown promising results in their MALT1 program and could potentially lead to new treatments for non-Hodgkin lymphomas. The company's participation in the AACR International Meeting highlights their commitment to advancing cancer research and finding new ways to treat this disease.
Filed Under: Business
0 Comments
Latest on The PennZone
- $5 - $20 Million in Sales for 2026; $25 - $40 Million for 2027 Projected with NASA Agreements; New MOU Signed to Improve Solar Tech in Space
- Costa Oil – 10 Minute Oil Change Opens 70th Location in Reed City, MI
- New Book: Cold War Sci-Fi Thriller Arrives Today
- BeeCool Bikes Unveils Next-Generation "Super Frame" with Bee Defender Series
- DEADLINE TOMORROW: Berger Montague Advises Petco Health and Wellness Company, Inc. (NASDAQ: WOOF) Investors to Inquire About a Securities Fraud Class Action by August 29, 2025
- University of South Pacific and Battery Pollution Technologies Forge Strategic Partnership to tackle Battery End-of-Life Challenges in the Pacific
- Shincheonji Tanzania Church Holds Revelation Bible Exam with Local Pastors and Believers
- Portland Med Spa Expands Service Offerings with Latest Aesthetic Technologies
- Growth Acceleration via Strategic Reverse Split After $10 Million Acquisition for Concerts.com and TicketStub.com; AI Powered Sports/Entertainment Co
- Hollywood Casting Director's Book Hits #1 on Amazon Before Release
- OddsTrader Projects Three Potential Elimination Games in Week 1 of College Football
- Century Fasteners Corp. Exhibiting at the 2025 International Fastener Expo
- JKS Financial Strengthens Regional Presence with New Office in Sewickley
- Donors Join Forces to Support Center for Microbial Medicine at Children's Hospital of Philadelphia
- Canvas Cloud AI Launches to Transform Cloud Education From Memorization to Mastery
- The Squires Group Becomes a Workday Partner
- From Vernon Hills to Mensa Before Kindergarten
- Benchmark International Faciltd the Trans Between Total Sales & Marketing Inc and Retail Rex Capital
- PermianMuseum.com adds Interstellar Visitor Video Gallery
- SOBREO Elixirs Debut in New York City, Defining a New Era in Inclusive Hospitality